Increased Skin Clearance and Quality of Life Improvement with Brodalumab Compared with Ustekinumab in Psoriasis Patients with Aggravating Lifestyle Factors.

Dermatol Ther (Heidelb) · 2021 · PMC8611142 · PMID 34606048

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

1 ); differences between the brodalumab and ustekinumab groups were statistically significant for subgroups with no, one, or two baseline risk factors, but did not reach statistical significance in the subgroup with three risk factors.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.